Abstract
The increasing incidence of diabetes mellitus (DM) and chronic periodontitis (CP) worldwide imposes a rethinking of individualized therapy for patients with both conditions. Central to bidirectional links between DM and CP is deregulated systemic inflammation and dysfunctional immune responses to altered-self and non-self. Control of blood glucose levels and metabolic imbalances associated with hyperglycemia in DM, and disruption of pathogenic subgingival biofilms in CP are currently the main therapeutic approaches for these conditions. Mounting evidence suggests the need to integrate immune modulatory therapeutics in treatment regimens that address the unresolved inflammation associated with DM and CP. The current review discusses the pathogenesis of DM and CP with emphasis on deregulated inflammation, current therapeutic approaches and the novel pro-resolution lipid mediators derived from -3 polyunsaturated fatty acids.
Keywords: Diabetes mellitus, periodontitis, inflammation, lipid mediators, pro-resolution therapeutics.
Current Pharmaceutical Design
Title:Therapeutic Targets for Management of Periodontitis and Diabetes
Volume: 22 Issue: 15
Author(s): Corneliu Sima and Thomas E. Van Dyke
Affiliation:
Keywords: Diabetes mellitus, periodontitis, inflammation, lipid mediators, pro-resolution therapeutics.
Abstract: The increasing incidence of diabetes mellitus (DM) and chronic periodontitis (CP) worldwide imposes a rethinking of individualized therapy for patients with both conditions. Central to bidirectional links between DM and CP is deregulated systemic inflammation and dysfunctional immune responses to altered-self and non-self. Control of blood glucose levels and metabolic imbalances associated with hyperglycemia in DM, and disruption of pathogenic subgingival biofilms in CP are currently the main therapeutic approaches for these conditions. Mounting evidence suggests the need to integrate immune modulatory therapeutics in treatment regimens that address the unresolved inflammation associated with DM and CP. The current review discusses the pathogenesis of DM and CP with emphasis on deregulated inflammation, current therapeutic approaches and the novel pro-resolution lipid mediators derived from -3 polyunsaturated fatty acids.
Export Options
About this article
Cite this article as:
Sima Corneliu and E. Van Dyke Thomas, Therapeutic Targets for Management of Periodontitis and Diabetes, Current Pharmaceutical Design 2016; 22 (15) . https://dx.doi.org/10.2174/1381612822666160216150338
DOI https://dx.doi.org/10.2174/1381612822666160216150338 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
A Comprehensive Study of Pharmacological Behaviors, Nano-Formulations, and Applications of Rosemary
The Natural Products Journal Diagnosis and Management of Chronic Coronary Artery Disease
Current Cardiology Reviews Gut Microbiota as a Therapeutic Target for Metabolic Disorders
Current Medicinal Chemistry Programming Apoptosis and Autophagy with Novel Approaches for Diabetes Mellitus
Current Neurovascular Research Gold Nanoparticle Based Systems in Genetics
Current Pharmacogenomics The Diabetic Foot
Current Pharmaceutical Design Contemporary Overview on Clinical Trials and Future Prospects of Hepato-protective Herbal Medicines
Reviews on Recent Clinical Trials The Effects of Medications Used for the Management of Diabetes and Obesity on Postprandial Lipid Metabolism
Current Diabetes Reviews Recent advances in the management of autoimmune myocarditis: insights from animal studies.
Current Pharmaceutical Design MicroRNAs as Candidate Drug Targets for Cardiovascular Diseases
Current Drug Targets Chronic Kidney Disease and Cardiovascular Disease: A Focus on Primary Care
Cardiovascular & Hematological Disorders-Drug Targets Nanotechnology Advanced Strategies for the Management of Diabetes Mellitus
Current Drug Targets Atorvastatin Inhibited ROS Generation and Increased IL-1β And IL-6 Release by Mononuclear Cells from Diabetic Patients
Endocrine, Metabolic & Immune Disorders - Drug Targets Metabolic Reprogramming of Human Cells in Response to Oxidative Stress: Implications in the Pathophysiology and Therapy of Mitochondrial Diseases
Current Pharmaceutical Design Soluble Forms of RAGE in Human Diseases: Clinical and Therapeutical Implications
Current Medicinal Chemistry Update on the Biologic Role of the Vitamin D Endocrine System
Current Vascular Pharmacology Rifaximin: The Revolutionary Antibiotic Approach for Irritable Bowel Syndrome
Mini-Reviews in Medicinal Chemistry Risk Factors of Alzheimers Disease Among Iranian Population
Current Alzheimer Research Natural Products Towards the Discovery of Potential Future Antithrombotic Drugs
Current Pharmaceutical Design Does Metabolic Syndrome or its Individual Components Affect Pain and Function in Knee Osteoarthritis Women?
Current Rheumatology Reviews